MorphoSys Announces Longer-term Phase 2 Results On Pelabresib In Myelofibrosis

(RTTNews) - MorphoSys AG (MOR, MPSYY.PK) reported results from analyses of the ongoing MANIFEST study, a phase 2 clinical trial of pelabresib in patients with myelofibrosis, a type of bone marrow cancer. The company said the latest analyses include longer-term data showing durable improvements in both spleen volume and symptom score beyond 24 weeks, with pelabresib plus ruxolitinib in JAK inhibitor-naïve patients. Also, translational data from MANIFEST was presented indicating the association of biomarkers with potential disease-modifying activity of pelabresib.

"Based on these and other MANIFEST findings presented this week, our confidence in pelabresib and the Phase 3 MANIFEST-2 study is high. We look forward to learning more as the trial progresses," said Tim Demuth, MorphoSys Chief Research and Development Officer.

For More Such Health News, visit rttnews.com.